Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page
- Check6 days agoChange DetectedThe page update is limited to metadata/UI changes: the revision label was updated from v3.0.0 to v3.0.1 and a 'Back to Top' link was added; there are no changes to core content, pricing, stock availability, or scheduling.SummaryDifference0.1%
- Check13 days agoChange DetectedThe web page has undergone significant updates, including the addition of new drug information for Lazertinib and Amivantamab, as well as numerous location details across various countries. Additionally, the facility name has been included, while some previous location entries and drug information have been removed.SummaryDifference19%
- Check20 days agoChange DetectedThe webpage has updated its date references, removing older dates from July 2025 and adding new dates in August 2025.SummaryDifference0.3%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check42 days agoChange DetectedThe web page has been updated from version 2.16.8 to version 2.16.11, indicating a revision in the content.SummaryDifference0.0%
- Check49 days agoChange DetectedThe page has been updated to reflect a new version (v2.16.8) and a new last update date (July 20, 2025), replacing the previous version (v2.16.6) and last update date (July 17, 2025).SummaryDifference0.7%
Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.